Harris AE, Metzler VM, Lothion-Roy J, Varun D, Woodcock CL, Haigh DB, Endeley C, Haque M, Toss MS, Alsaleem M et al..
2022.
Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer.. Front Endocrinol (Lausanne). 13:1006101.
Kopparapu PKumar, Boorjian SA, Robinson BD, Downes M, Gudas LJ, Mongan NP, Persson JL.
2013.
Expression of cyclin d1 and its association with disease characteristics in bladder cancer.. Anticancer Res. 33(12):5235-42.
Kopparapu PKumar, Boorjian SA, Robinson BD, Downes M, Gudas LJ, Mongan NP, Persson JL.
2013.
Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer.. Anticancer Res. 33(6):2381-90.
Raman JD, Mongan NP, Tickoo SK, Boorjian SA, Scherr DS, Gudas LJ.
2005.
Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder.. Clin Cancer Res. 11(24 Pt 1):8570-6.
Metzler VM, de Brot S, Haigh DB, Woodcock CL, Lothion-Roy J, Harris AE, Nilsson EM, Ntekim A, Persson JL, Robinson BD et al..
2023.
The KDM5B and KDM1A lysine demethylases cooperate in regulating androgen receptor expression and signalling in prostate cancer.. Front Cell Dev Biol. 11:1116424.
Williams RM, Shah J, Mercer E, Tian HS, Thompson V, Cheung JM, Dorso M, Kubala JM, Gudas LJ, de Stanchina E et al..
2021.
Kidney-Targeted Redox Scavenger Therapy Prevents Cisplatin-Induced Acute Kidney Injury.. Front Pharmacol. 12:790913.